CZMWY

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Carl Zeiss Meditec A G

CEO
Ludwin Monz
Employees
0
Headquarters

Goeschwitzer Strasse 51-52
Jena, Thueringen 07745
Phone: 4936412200
https://www.zeiss.de/meditec-ag/

News

Baader Helvea cuts Carl Zeiss Meditec stock PT on China and US near-term headwinds
Jun 20, 2024 11:12am

https://www.investing.com/news/company-news/baader-helvea-cuts-carl-zeiss-meditec-stock-pt-on-china-and-us-nearterm-headwinds-93CH-3489774


Source:Investing.com
Carl Zeiss Meditec AG: 2023/24 Revenue & EBIT Forecast Cut Amid Slow Recovery
Jun 17, 2024 08:15am

Facing a sluggish recovery in the equipment sector, the revenue and EBIT forecasts for fiscal year 2023/24 have been revised downward. Preliminary figures show a notable decline, prompting strategic cost-cutting measures. Jetzt den vollständigen Artikel lesen


Source:Wallstreet:Online
EQS-Adhoc: Carl Zeiss Meditec AG: Revenue and EBIT forecast for fiscal year 2023/24 reduced amid slower than expected recovery of equipment business
Jun 17, 2024 08:09am

EQS-Ad-hoc: Carl Zeiss Meditec AG / Key word(s): Change in Forecast/Profit Warning Carl Zeiss Meditec AG: Revenue and EBIT forecast for fiscal year 2023/24 reduced amid slower than expected recovery of equipment business 17-Jun-2024 / 10:09 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News Jetzt den vollständigen Artikel lesen


Source:Wallstreet:Online
Carl Zeiss Meditec AG: Revenue and EBIT forecast for fiscal year 2023/24 reduced amid slower than expected recovery of equipment business
Jun 17, 2024 08:09am

Carl Zeiss Meditec AG / Key word(s): Change in Forecast/Profit Warning Carl Zeiss Meditec AG: Revenue and EBIT forecast for fiscal year 2023/24 reduced amid slower than expected recovery of equipment business 17-Jun-2024 / 10:09 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Revenue and EBIT forecast for fiscal year 2023/24 reduced amid slower than expected recovery of equipment business Jena, June 17, 2024 In the first 8 months of fiscal year (FY) 2023/24 as of May 31, 2024, excluding the contribution from the acquisition of Dutch Ophthalmic Research Center B.V. (DORC), Carl Zeiss Meditec AG (ISIN: DE0005313704) had preliminary revenue of € 1,258 million (prior year: € 1,297 million, -3%). Preliminary operating profit (EBIT) amounted to € 135 million (prior year: € 183 million, -26%), excluding the contribution from the acquisition of DORC as well as integration cost related to the acquisition.


Source:EQS News